Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00017186 · ClinicalTrials.gov registry record · Phase 2

Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma

A Phase 2 study of Malignant Mesothelioma, sponsored by Alliance for Clinical Trials in Oncology.

Completed
Registry status
Phase 2
Development phase
69
Enrollment target
20
Study locations

NCT00017186 is a Phase 2 study of Malignant Mesothelioma that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 69 participants, roughly in line with the 70-participant average among 11 other Malignant Mesothelioma trials with a reported enrollment target. The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00017186, a Phase 2 study of Malignant Mesothelioma, has completed, sponsored by Alliance for Clinical Trials in Oncology.

COMPLETED
Registry status
Phase 2
Development phase
69 participants
Enrollment target
20
Study locations

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining gemcitabine and epirubicin in treating patients who have malignant mesothelioma.

Conditions Studied

Malignant Mesothelioma

Interventions

  • DRUG epirubicin hydrochloride
  • DRUG gemcitabine hydrochloride

Study Locations (20)

Minnesota

  • CCOP - Duluth - Duluth
  • Mayo Clinic Cancer Center - Rochester
  • Coborn Cancer Center - Saint Cloud
  • CCOP - Metro-Minnesota - Saint Louis Park

Iowa

  • CCOP - Cedar Rapids Oncology Project - Cedar Rapids
  • CCOP - Iowa Oncology Research Association - Des Moines
  • Siouxland Hematology-Oncology - Sioux City

Illinois

  • CCOP - Illinois Oncology Research Association - Peoria
  • CCOP - Carle Cancer Center - Urbana

North Dakota

  • Medcenter One Health System - Bismarck
  • CCOP - Merit Care Hospital - Fargo

Alabama

  • MBCCOP - Gulf Coast - Mobile

Arizona

  • CCOP - Mayo Clinic Scottsdale Oncology Program - Scottsdale

Florida

  • Mayo Clinic - Jacksonville - Jacksonville

Kansas

  • CCOP - Wichita - Wichita

Trial Details

FieldValue
Enrollment Target 69 participants
Start Date 2001-07
Est. Completion 2008-05
Phase Phase 2

Sponsor

Alliance for Clinical Trials in Oncology

446 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00017186

The ClinicalTrials.gov registry entry for NCT00017186 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 70-participant average among 11 other Malignant Mesothelioma trials with a reported enrollment target. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Malignant Mesothelioma appearing as the primary indexed condition, and to 2 interventions - of which epirubicin hydrochloride is the first listed.

NCT00017186 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Minnesota, Iowa, Illinois.

Frequently Asked Questions

What is clinical trial NCT00017186 about?

NCT00017186 is a clinical study titled "Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining gemcitabine and epirubicin in treating patients who have ma...

What is the current status of trial NCT00017186?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 69 participants. The study started on 2001-07. Estimated completion is 2008-05.

What conditions does trial NCT00017186 study?

This clinical trial studies the following conditions: Malignant Mesothelioma.

What interventions are being tested in trial NCT00017186?

The interventions under investigation include: epirubicin hydrochloride (DRUG), gemcitabine hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00017186?

This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00017186 being conducted?

This trial has 20 study locations across Alabama, Arizona, Florida, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Malignant Mesothelioma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Malignant Mesothelioma

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.